HUTCHMED China Ltd (HCM) - Total Assets

Latest as of June 2025: GBX1.78 Billion GBX ≈ $216.08K USD

Based on the latest financial reports, HUTCHMED China Ltd (HCM) holds total assets worth GBX1.78 Billion GBX (≈ $216.08K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check HCM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

HUTCHMED China Ltd - Total Assets Trend (2005–2024)

This chart illustrates how HUTCHMED China Ltd's total assets have evolved over time, based on quarterly financial data. Explore HCM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

HUTCHMED China Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

HUTCHMED China Ltd's total assets of GBX1.78 Billion consist of 83.7% current assets and 16.3% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 12.1%
Accounts Receivable GBX167.74 Million 13.2%
Inventory GBX50.40 Million 4.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX167.74 Million 13.2%
Goodwill GBX0.00 0.0%

Asset Composition Trend (2005–2024)

This chart illustrates how HUTCHMED China Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is HUTCHMED China Ltd worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: HUTCHMED China Ltd's current assets represent 83.7% of total assets in 2024, an increase from 47.7% in 2005.
  • Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, up from 8.9% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 19.0% in 2005.
  • Asset Diversification: The largest asset category is intangible assets at 13.2% of total assets.

HUTCHMED China Ltd Competitors by Total Assets

Key competitors of HUTCHMED China Ltd based on total assets are shown below.

Company Country Total Assets
Haleon plc
NYSE:HLN
USA $32.57 Billion
Viatris Inc
NASDAQ:VTRS
USA $36.83 Billion
Neuland Laboratories Limited
NSE:NEULANDLAB
India Rs25.34 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.60 Billion
Shenzhen Chipscreen Biosciences Co
SHG:688321
China CN¥3.63 Billion
Tianjin Ringpu Bio Tech
SHE:300119
China CN¥7.80 Billion
China Animal Husbandry Industry Co Ltd
SHG:600195
China CN¥9.32 Billion
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915
China CN¥4.78 Billion

HUTCHMED China Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.65 2.81 3.35
Quick Ratio 4.65 2.68 3.23
Cash Ratio 0.00 0.00 0.00
Working Capital GBX1.25 Billion GBX674.97 Million GBX372.34 Million

HUTCHMED China Ltd - Advanced Valuation Insights

This section examines the relationship between HUTCHMED China Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.97
Latest Market Cap to Assets Ratio 0.01
Asset Growth Rate (YoY) -0.4%
Total Assets GBX1.27 Billion
Market Capitalization $18.30 Million USD

Valuation Analysis

Below Book Valuation: The market values HUTCHMED China Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: HUTCHMED China Ltd's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for HUTCHMED China Ltd (2005–2024)

The table below shows the annual total assets of HUTCHMED China Ltd from 2005 to 2024.

Year Total Assets Change
2024-12-31 GBX1.27 Billion
≈ $155.03K
-0.44%
2023-12-31 GBX1.28 Billion
≈ $155.71K
+24.32%
2022-12-31 GBX1.03 Billion
≈ $125.25K
-25.00%
2021-12-31 GBX1.37 Billion
≈ $167.01K
+89.56%
2020-12-31 GBX724.12 Million
≈ $88.10K
+55.68%
2019-12-31 GBX465.12 Million
≈ $56.59K
-12.59%
2018-12-31 GBX532.12 Million
≈ $64.74K
-11.01%
2017-12-31 GBX597.93 Million
≈ $72.75K
+74.61%
2016-12-31 GBX342.44 Million
≈ $41.66K
+49.05%
2015-12-31 GBX229.75 Million
≈ $27.95K
+4.94%
2014-12-31 GBX218.94 Million
≈ $26.64K
+17.92%
2013-12-31 GBX185.67 Million
≈ $22.59K
-11.36%
2012-12-31 GBX209.47 Million
≈ $25.49K
+7.54%
2011-12-31 GBX194.77 Million
≈ $23.70K
+21.79%
2010-12-31 GBX159.93 Million
≈ $19.46K
+25.18%
2009-12-31 GBX127.75 Million
≈ $15.54K
+8.31%
2008-12-31 GBX117.96 Million
≈ $14.35K
-7.53%
2007-12-31 GBX127.56 Million
≈ $15.52K
-4.12%
2006-12-31 GBX133.04 Million
≈ $16.19K
+111.58%
2005-12-31 GBX62.88 Million
≈ $7.65K
--

About HUTCHMED China Ltd

LSE:HCM UK Drug Manufacturers - Specialty & Generic
Market Cap
$18.30 Million
GBX150.38 Billion GBX
Market Cap Rank
#25389 Global
#266 in UK
Share Price
GBX175.00
Change (1 day)
+0.57%
52-Week Range
GBX172.00 - GBX286.00
All Time High
GBX624.00
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more